Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients
DOI:
https://doi.org/10.3889/oamjms.2016.011Keywords:
hemodialysis, cardiac troponin T, natriuretic peptide, C-reactive protein, left ventricular hypertrophyAbstract
BACKGROUND: Cardiac biomarkers are often elevated in dialysis patients showing the presence of left ventricular dysfunction. The aim of the study is to establish the plasma levels of high-sensitivity cardiac troponin T (hs TnT), precursor of B-natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hs CRP) and their relation to the presence of left ventricular hypertrophy (LVH) in patients undergoing hemodialysis without signs of acute coronary syndrome or heart failure.
MATERIAL AND METHODS: Were studied 48 patients - 26 men and 22 women. Pre and postdialysis levels of hs cTnT, NT-proBNP and hs CRP were measured at week interim procedure. Patients were divided in two groups according to the presence of echocardiographic evidence of LVH - gr A - 40 patients (with LVH), and gr B - 8 patients (without LVH).
RESULTS: In the whole group of patients was found elevated predialysis levels of all three biomarkers with significant increase (p < 0.05) after dialysis with low-flux dialyzers. Predialysis values of NT-proBNP show moderate positive correlation with hs cTnT (r = 0.47) and weaker with hs CRP (r = 0.163). Such dependence is observed in postdialysis values of these biomarkers. There is a strong positive correlation between the pre and postdialysis levels: for hs cTnT (r = 0.966), for NT-proBNP (r = 0.918) and for hs CRP (r = 0.859). It was found a significant difference in the mean values of hs cTnT in gr. A and gr. B (0.07 ± 0.01 versus 0.03 ± 0.01 ng /mL, p < 0.05) and NT-proBNP (15,605.8 ± 2,072.5 versus 2,745.5 ± 533.55 pg /mL, p < 0.05). Not find a significant difference in hs CRP in both groups.
CONCLUSIONS: The results indicate the relationship of the studied cardiac biomarkers with LVH in asymptomatic patients undergoing hemodialysis treatment.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492–1498.
http://dx.doi.org/10.1111/j.1523-1755.2004.00530.x DOI: https://doi.org/10.1111/j.1523-1755.2004.00530.x
PMid:15086493
Parfrey PS, Collingwood P, Foley RN, Bahrle A. Left ventricular disorders detected by M-mode echocardiography in chronic uremia. Nephrol Dial Transplant. 1996;11:1328-1331.
http://dx.doi.org/10.1093/ndt/11.7.1328 DOI: https://doi.org/10.1093/ndt/11.7.1328
PMid:8672032
Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 1993;65:212-214.
http://dx.doi.org/10.1159/000187476 DOI: https://doi.org/10.1159/000187476
PMid:8247182
Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4:1486-1490. DOI: https://doi.org/10.1681/ASN.V471486
PMid:8161730
Parfrey PS, Griffiths SM, Harnett JD, et al. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease and ischemic heart disease in dialysis patients. Am J Nephrol. 1990;10:213-221.
http://dx.doi.org/10.1159/000168084 DOI: https://doi.org/10.1159/000168084
PMid:2143353
Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277-1285.
http://dx.doi.org/10.1093/ndt/11.7.1277 DOI: https://doi.org/10.1093/ndt/11.7.1277
PMid:8672023
Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008;3:920-929.
http://dx.doi.org/10.2215/CJN.04571007 DOI: https://doi.org/10.2215/CJN.04571007
PMid:18372318
Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia - beyond coronary heart disease. Semin Dial. 2008;21:308-318.
http://dx.doi.org/10.1111/j.1525-139X.2008.00454.x DOI: https://doi.org/10.1111/j.1525-139X.2008.00454.x
PMid:18627569
Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int. 2009;75:771-773.
http://dx.doi.org/10.1038/ki.2009.35 DOI: https://doi.org/10.1038/ki.2009.35
PMid:19337217
Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27:159-163.
http://dx.doi.org/10.1159/000100106
PMid:17317951
Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-192.
http://dx.doi.org/10.1038/ki.1995.22 DOI: https://doi.org/10.1038/ki.1995.22
PMid:7731145
Cerasola G, Nardi E, Palermo A, et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol. 2011;24:1-10.
http://dx.doi.org/10.5301/JN.2010.2030 DOI: https://doi.org/10.5301/JN.2010.2030
PMid:20437402
Xu X, Hu X, Zhang P, Zhao L, Wessale JL. Bache RJ. Chen Y: Xantine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14:746-753.
http://dx.doi.org/10.1016/j.cardfail.2008.06.006 DOI: https://doi.org/10.1016/j.cardfail.2008.06.006
PMid:18995179 PMCid:PMC2610415
Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi AR, Barsanti R, Padovani C, Gavras H. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens. 2004;17:1163-1169.
http://dx.doi.org/10.1016/j.amjhyper.2004.07.017 DOI: https://doi.org/10.1016/j.amjhyper.2004.07.017
PMid:15607624
McRae JM, Levin A, Belenkie I. The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial. 2006;19:349-352.
http://dx.doi.org/10.1111/j.1525-139X.2006.00185.x DOI: https://doi.org/10.1111/j.1525-139X.2006.00185.x
PMid:16970729
Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009;16:31-38.
http://dx.doi.org/10.1038/cdd.2008.163 DOI: https://doi.org/10.1038/cdd.2008.163
PMid:19008922
Dorm GW 2nd: Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovasc Res. 2009;81:465-473.
http://dx.doi.org/10.1093/cvr/cvn243 DOI: https://doi.org/10.1093/cvr/cvn243
PMid:18779231 PMCid:PMC2721651
Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial. 2004;17:299-303.
http://dx.doi.org/10.1111/j.0894-0959.2004.17331.x DOI: https://doi.org/10.1111/j.0894-0959.2004.17331.x
PMid:15250922
Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27:159-163.
http://dx.doi.org/10.1159/000100106 DOI: https://doi.org/10.1159/000100106
PMid:17317951
Sakurabayashi T, Miyazaki S, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Hirasawa Y. L-Carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J. 2008;72: 926-931.
http://dx.doi.org/10.1253/circj.72.926 DOI: https://doi.org/10.1253/circj.72.926
PMid:18503218
Strozecki P, et al. Parathormon. calcium. phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23:115-126.
http://dx.doi.org/10.1081/JDI-100001291 DOI: https://doi.org/10.1081/JDI-100001291
PMid:11256521
Di Lullo L, Floccari F, Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract. 2011;118:c258-c262.
http://dx.doi.org/10.1159/000321867 DOI: https://doi.org/10.1159/000321867
PMid:21196771
Kim BS, Jeon DS, Shin MJ, et al. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189-195.
http://dx.doi.org/10.1159/000085585 DOI: https://doi.org/10.1159/000085585
PMid:15863980
Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006;175:611-7.
http://dx.doi.org/10.1503/cmaj.060236 DOI: https://doi.org/10.1503/cmaj.060236
PMid:16966666 PMCid:PMC1559415
Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105-7.
http://dx.doi.org/10.1096/fj.02-0796fje DOI: https://doi.org/10.1096/fj.02-0796fje
Konstam MA. Natriuretic peptides and cardiovascular events: More than a stretch. JAMA. 2007;297:212-4.
http://dx.doi.org/10.1001/jama.297.2.212 DOI: https://doi.org/10.1001/jama.297.2.212
PMid:17213406
Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ. 2005;14:78-84.
http://dx.doi.org/10.1016/j.hlc.2005.03.002 DOI: https://doi.org/10.1016/j.hlc.2005.03.002
PMid:16352258
Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol. 2010;23:465-71.
PMid:20540041
Heeschen C, Deu A, Langenbrink L, Goldmann BU, Hamm CW. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. Clin Biochem. 2000;33:359-368.
http://dx.doi.org/10.1016/S0009-9120(00)00144-2 DOI: https://doi.org/10.1016/S0009-9120(00)00144-2
Resić H, Ajanović S, Kukavica N, et al. Plasma levels of brain natriuretic peptides and cardiac troponin in hemodialysis patients. Bosnian Journal of basic medical sciences. 2009;9:137-141. DOI: https://doi.org/10.17305/bjbms.2009.2833
PMid:19485946
Dervisoglu E, Kozdag G, Etiler N, Kalender B. Association of glomerular filtration rate and inflammation with left ventricular hypertrothy in chronic kidney disease patients. Hippokratia. 2012;16:137-142.
PMid:23935269 PMCid:PMC3738415
Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-327.
http://dx.doi.org/10.1053/j.ajkd.2005.04.031 DOI: https://doi.org/10.1053/j.ajkd.2005.04.031
PMid:16112052
Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118-1122.
http://dx.doi.org/10.1161/01.HYP.0000185463.27209.b0 DOI: https://doi.org/10.1161/01.HYP.0000185463.27209.b0
PMid:16216991
Ratto E, Leoncini G, Viazzi F, et al. C-reactive protein and target organ damage in untreated patients with primary hypertension. J Am Soc Hypertens. 2007;1:407- 413.
http://dx.doi.org/10.1016/j.jash.2007.09.003 DOI: https://doi.org/10.1016/j.jash.2007.09.003
PMid:20409873
Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50: 1071–1074.
http://dx.doi.org/10.1373/clinchem.2003.030692 DOI: https://doi.org/10.1373/clinchem.2003.030692
PMid:15161726
Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest. 2004;125:1877–1884.
http://dx.doi.org/10.1378/chest.125.5.1877 DOI: https://doi.org/10.1378/chest.125.5.1877
PMid:15136402
Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–1376.
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.005264 DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.005264
PMid:21422391 PMCid:PMC3072024
Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–1965.
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.609974 DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.609974
PMid:16618821
Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643–1652.
http://dx.doi.org/10.1681/ASN.2008010012 DOI: https://doi.org/10.1681/ASN.2008010012
PMid:18322158
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0